Gamma-retroviruses are commonly used to deliver genes to cells. Previously, we demonstrated that the synthetic anti-glucocorticoid and anti-progestin agent, mifepristone, increased gamma-retroviral infection efficiency in different target cells, independent of viral titer. In this study, we examine how this occurs. We studied the effect of mifepristone on different steps of viral infection (viral entry, viral survival, viral DNA synthesis and retrovirus integration into the host genome) in three distinct retroviral backbones using different virus recognition receptors. We also tested the potential role of glucocorticoid and progesterone receptors in mediating mifepristone's ability to increase gamma-retroviral infectivity. We show that mifepristone increases gamma-retroviral infection efficiency by facilitating viral integration into the host genome and that this effect seems to be due to mifepristone's anti-glucocorticoid, but not its anti-progestin, activity. These results suggest that inhibition of the glucocorticoid receptor enhances retroviral integration into the host genome and indicates that cells may have a natural protection again retroviral infection that may be reduced by glucocorticoid receptor antagonists.
Introduction
Retroviral vector-mediated gene transfer is the easiest way for stable gene delivery into cells and can be used to permanently modify the host cell nuclear genome. Previously, we showed that the synthetic glucocorticoid and progesterone receptor antagonist, mifepristone, increased retroviral infectivity of uninfected target cells independent of viral titer in a moloney murine leukemia virus (MMLV)-based gene delivery system. 1 The ability of mifepristone to increase retroviral infectivity was demonstrated in several different types of target cells, including rat pulmonary artery smooth muscle and endothelial cells, human epithelial cells and a glioblastoma cell line. The mechanism, through which this occurred, however, was not clear.
In this study, we demonstrate that mifepristone increases gamma-retroviral infection efficiency by facilitating the integration of the viral genome into the host genome, a process that is mediated by mifepristone's antagonist activity on the glucocorticoid receptor.
Results

Mifepristone increases infection efficiency of different gamma-retroviruses
The classification of retroviruses is arranged by computer analysis of genomes, based primarily on comparisons of the size and morphological characteristics of the viral genome. All gamma-retroviruses have similarities in genome organization, but each possesses individual characteristics. Moloney murine leukemia virus-based vectors are produced by replacing the viral genes required for replication with the desired genes to be transferred, and along with other vectors are currently used as gene transfer vehicles. 2 The murine stem cell virus is an important derivative of MMLV, which has been optimized for introducing and expressing target genes into pluripotent cell lines, including murine and human hematopoietic embryonic stem cells, and embryonal carcinoma cells that are usually resistant to retroviral infection. 3 The friend murine embryonic stem cell virus, that is a hybrid viral backbone (friend mink cell focus-forming/murine embryonic stem cell virus) was also designed to optimize infection and protein expression in primary hematopoietic cells. 4 These last two retroviral backbones can be used to infect the same types of cells as MMLV.
We investigated whether mifepristone could also increase the target cell infectivity of these popular gamma-retroviral systems. Gamma-retroviral backbones containing genes encoding fluorescent proteins as reporters were propagated in Phoenix ecotropic packaging cells. Viral-conditioned supernatant was collected and applied to target cells (rat pulmonary microvascular endothelial cells, PMVEC). Figure 1a shows that mifepristone at 1 mmol/l concentration almost doubled the percentage of infected cells regardless of the viral backbone. This suggests that the ability of mifepristone to increase infectivity of gamma-retroviruses is not restricted to MMLV retroviral vectors, but also occurs in other popular gamma-retroviral gene delivery vectors. In contrast, mifepristone did not increase the target cell infectivity of lentiviral vectors (packed into vesicular stomatitis virus glycoprotein (VSV-G)-based viral particles).
Mifepristone increases target cell infection efficiency independent of viral or target cell recognition receptors
A viral receptor is conventionally defined as a component(s) on the cell surface to which a virus specifically binds and which may result in virus entry. Virus entry occurs after fusion between the retroviral envelope and the cellular plasma membrane. 5 To determine whether the type of viral receptor was critical to mifepristone's ability to increase target cell infectivity, we infected cells with MMLV packaged into viral particles with different envelope proteins-ecotropic, amphotropic and VSV-G based pantropic. The ecotropic envelope proteins recognize mouse cationic amino acid transporter-1 (mCAT1) 6 and can efficiently infect a broad range of mouse and rat cells. Amphotropic viral envelope proteins recognize the amphotropic receptor (Ram-1) and infect a broad range of mammalian cells. 7 Viral entry with VSV-G pantropic envelope glycoproteins from the vesicular stomatitis virus does not require a cell surface receptor, but mediates viral entry through lipid binding and plasma membrane fusion. 8 As shown in Figure 1b , the infection efficiency of rat PMVEC varied with the different viral particles, with VSV-G envelope glycoprotein demonstrating the greatest baseline infectivity, whereas amphotropic viral particles demonstrating the least. Although the baseline infectivity of ecotropic, amphotropic and VSV-G-based viruses was different (amphotropic receptors are less abundant in rodent cells compared with ecotropic ones, whereas VSV-G-based viruses do not use any protein receptors for cell entry), mifepristone doubled the percentage of infected cells in each case. These results suggest that the ability of mifepristone to increase target cell infectivity is not dependent on the type of envelope protein expressed by the viral particles.
Adding mifepristone after exposure to retrovirus still increases viral infection efficiency
Target cell entry is the first step of viral infection. This requires contact between the viral envelope and the cell membrane. Receptors on the viral envelope interact with complementary receptors on the cell membrane and this attachment causes the two membranes to remain in mutual proximity. To enter the cell through the phospholipid bilayer membrane, viral receptors attach to the receptors on the surface of the cell and either puncture the cell membrane or allow the fusion of the viral envelope with the host cell. The virus's envelope then releases its contents into the cell. 9 To determine whether mifepristone increased retroviral infection efficiency by facilitating viral entry into target cells, PMVECs were infected for 1 h in the absence of mifepristone. Cells were then washed (to remove the virus) and incubated in fresh medium for an additional 1 h. This allowed sufficient time for the virus to enter the cell, but not sufficient time to complete its infection cycle. Mifepristone (at 1 mmol l À1 concentration) was then added to the medium. After 72 h, target cells were trypsinized and analyzed for green fluorescent protein (GFP) expression by fluorescence activated cell sorting (FACS). Figure 2 demonstrates that adding mifepristone after the initial infection had occurred (that is, after the virus had been removed from the medium following its 1 h incubation) also increased viral infection efficiency approximately twofold (from 2.1 to 3.7%). The lower infection rate seen in Figure 3 compared with Figure 1 is due to the shorter retroviral incubation time (1 versus 18 h). This result suggests that the increased infection efficiency seen with mifepristone is not due to its effect on viral entry into target cells.
Mifepristone did not promote retroviral infection in nondividing cells
Gamma-retroviruses and many other RNA viruses can only infect dividing cells because they must access the host DNA to replicate. The interior of the nucleus is separated from the cytoplasm by a double-layer membrane called the nuclear envelope. Embedded in the nuclear envelope are nuclear pores, which act like selective filters that allow diffusion of ions and molecules, but nothing larger. 10 Gamma-retroviruses, therefore, cannot enter the nuclear compartment of nondividing cells and integrate into the host genome. As cells undergo replication and division, the nuclear envelope becomes more permeable, which allows greater cytoplasmic-nuclear trafficking and allows viruses to enter the nucleus. To determine whether mifepristone's ability to increase retroviral infection efficiency was due to its ability to infect nondividing cells, we compared the infection efficiency in dividing (growing) and nondividing (confluent) PMVECs with or without mifepristone. We grew cells to either 100% confluency (to induce cell arrest) or 15% confluency and then infected them with MMLV (at the same multiple of infectivity) in the presence of either 1 mmol l À1 of mifepristone or vehicle (EthOH). After 72 h, target cells were trypsinized and analyzed for GFP by FACS as previously described. Figure 3 demonstrates that the retrovirus was only able to infect dividing cells and the presence of mifepristone had no effect on this.
Mifepristone does not prolong survival of nonintegrated gamma-retroviral intermediates in infected cells
As transduction of target cells by gamma-retroviruses is dependent on cell replication, it is important to know how long a virus, which has successfully entered the target cell, retains its ability to integrate. Some authors have demonstrated that if cells have not divided within 6 h of infection, gene transfer does not occur. 11 This suggests that retroviruses do not remain viable within the cell cytoplasm for a prolonged period of time. Other studies have shown that growth-arrested cells infected with retroviruses can undergo infection later; however, suggesting that some stable viral intermediates can persist in growth-arrested cells. This intermediate may be viral RNA, viral DNA (after reverse transcriptase) or a mixture of partially reverse-transcribed forms. The intracellular half-life of MMLV has been determined to be in the range of 5.5-7.5 h. 11, 12 A potential mechanism by which mifepristone could increase the number of infected cells would be to prolong survival of the virus in infected but temporarily arrested cells. To evaluate this hypothesis, we tested the ability of mifepristone to increase retroviral infectivity of growtharrested cultured rat PMVECs, as they reentered the cell cycle over 48 h. Rat PMVEC stop proliferating once they attain confluence and therefore are resistant to retroviral infection. We have previously demonstrated that once these growth-arrested confluent cells are reseeded at lower confluency, they start to enter the S-phase approximately 24 h and G2-M phase about 30 h later. Figures 4a and b show the percentage of PMVECs entering G2-M phase at various time points after their reseeding from a confluent monolayer. Within this first 30 h after reseeding, cells are not dividing and therefore although they may be able to take up the virus, they are unable to complete an infection cycle by integrating it into the host genome. 
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The PMVECs that were growth-arrested and then reseeded at lower confluence as described above, were infected at various time points after reseeding in the presence of 1 mmol l À1 mifepristone or vehicle. Cells were incubated with virus for only 12 h, but at different time points after reseeding. After 72 h, the cells were analyzed for GFP using FACS. Figure 4d shows that cells infected immediately after reseeding (that is, 0-12 h) demonstrated less infection efficiency compared with cells infected later (24-36 and 36-48 h). As arrested cells can take up the virus, but are unable to integrate it into the host genome, the decreased infection efficiency in cells infected immediately after reseeding was likely due to the fact that by the time these cells began to divide (approximately 30 h), most of the virus that had been taken up by the cells was already degraded. By the time the early-infected cells begin to divide (at about 30 h), the virus has been degraded and is no longer capable of integration. As expected, mifepristone increased the infectivity rate at all time points (about 2.9-fold), but did not demonstrate an enhanced effect at the earlier time points (Figure 4e ). This suggests that mifepristone did not prolong the survival of nonintegrated viral intermediates in these infected but temporarily nondividing target cells. Had mifepristone prolonged viral survival, the earlier infected cells should have demonstrated a greater infectivity rate when compared with those cells infected later. Figure 4e , however, demonstrates that the increase in infectivity rate after incubation with mifepristone was similar at all time points. This correlates with our previously published results 1 demonstrating that mifepristone does not prolong viral viability in cell culture. Figure 4c shows representative flow cytometry data of retroviral infectivity for all experimental conditions.
Mifepristone does not enhance viral DNA synthesis in target cells
As mifepristone did not affect viral entry or survival in target cells but did increase the number of stably infected cells, we examined whether mifepristone stimulated other post-infection events in target cells, including viral DNA synthesis (reverse transcriptase) or integration into the host genome. Reverse transcription-the transcribing of genetic information from RNA to DNA-is a hallmark of the retroviral replication cycle. The enzyme reverse transcriptase catalyzes this process and has a critical role in viral cycling. 13 To determine whether viral DNA synthesis was stimulated by mifepristone, we performed quantitative PCR (qPCR) on total DNA isolated from target cells at various time points after infection ( Figure 5a ). To better synchronize infection events, we exposed target cells to MMLV for only 1 h in the presence of mifepristone or vehicle. After that, virus was removed from the medium. The viral DNA content in infected cells was measured by qPCR using primers to the GFP region of viral DNA. Mifepristone or vehicle was present in the medium from the beginning of infection until analysis (up to 7 days). Viral DNA content peaked 6 h after infection and then began to decrease. There was no difference in viral DNA levels between mifepristone-and vehicle-treated cells in the first 6 h, suggesting that mifepristone did not affect viral DNA Figure 4 Mifepristone had no effect on the survival or stability of the nonintegrated gamma-retrovirus in infected cells. Growth-arrested pulmonary microvascular endothelial cells (PMVECs) from a confluent monolayer were trypsinized and reseeded at 15% confluency. Cell cycle progression was monitored by propidium iodide (PI) staining using fluorescence-activated cell sorting (FACS). Figure 1 and to our earlier published results. As the viral DNA content during log phase replication (0-6 h) was not affected by mifepristone, it is unlikely that mifepristone increased target cell infectivity by stimulating viral reverse transcription.
Mifepristone enhances viral integration into host DNA
Although newly synthesized viral DNA can persist either as linear forms, one LTR circles or two LTR circles for a period of time, ultimately this viral DNA must be either integrated (to complete an infection cycle) or degraded. If it is integrated into the host genome, viral DNA should be detectable within the genomic DNA immediately after incorporation. To examine whether mifepristone increased the amount of viral DNA integrated into the host genome, we infected cells with MMLV for 1 h in the presence or absence of mifepristone, isolated total DNA from target cells at the time points described above and resolved the DNA on an agarose gel. The 4-kb DNA fragments (the size of nonintegrated viral DNA) and genomic DNA (450 kb) were cut out and the DNA from each fraction was extracted and analyzed for the presence of viral sequences by qPCR. The level of free viral DNA (that is, the viral 4-kb DNA fragment) was markedly increased 6 h after infection in both vehicle-and mifepristone-treated cells and then declined toward baseline by 3 days (Figure 5b ). At no time did the mifepristone-treated cells demonstrate greater free viral DNA levels than vehicle-treated cells. This is consistent with our previous observation that mifepristone did not increase viral DNA synthesis. In contrast, the amount of viral DNA that was integrated into the genomic fraction was greater in mifepristonetreated cells at all time points (Figure 5c ). This increase in the level of integrated viral DNA was the only event in Figure 5 Mifepristone enhances viral integration into host DNA. Pulmonary microvascular endothelial cells (PMVECs) were infected with ecotropic moloney murine leukemia virus (MMLV) for 1 h in the presence of 1 mmol l À1 mifepristone or vehicle control. The virus was removed by washing and cells were then cultured in fresh medium supplemented with 1 mmol l À1 mifepristone or vehicle until analysis. (a) Total DNA (host and viral) was extracted from target cells and the presence of viral DNA (using primers to the green fluorescent protein (GFP)-coding sequence that is present only in the viral DNA) was determined. Total target cell DNA was extracted and then separated in a 0.8% agarose gel. Nonintegrated viral DNA migrates to about 4 kb, whereas genomic DNA migrates 450 kb. Each fraction was extracted from the gel and analyzed for the presence of viral DNA separately. For each time point, equal amounts of DNA were examined. (b) Quantitative PCR (qPCR) from the 4-kb fragment representing the relative amounts of nonintegrated viral DNA in mifepristone-or vehicle-treated cells. (c) qPCR from the 450 kb genomic DNA representing the relative amounts of integrated viral DNA in mifepristone-or vehicle-treated cells. qPCR results in each experimental design were normalized to the signal obtained from vehicle-treated cells 1 h after infection. DNA was extracted and analyzed 1, 6 and 24 h and also 3 and 7 days after initial infection. These qPCR results were confirmed using another set of primers encoding for the internal ribosome entry site of viral DNA (present in the pBMN-GFP vector; n ¼ 4 experiments; *Po0.05).
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the viral infection cycle that was altered by the presence of mifepristone.
Mifepristone increases gamma-retroviral infectivity through its effect on the glucocorticoid receptor
Mifepristone is a synthetic steroid that can act as an antagonist to both glucocorticoid and progesterone receptors.
14 At the molecular level, mifepristone binds to the glucocorticoid or progesterone receptors with high affinity, interacting with the receptor at the phenylaminodimethyl group in the 11b-position within a specific region of the receptor-binding pocket. 15 Mifepristone induces a conformational change within the ligandbinding domain and reduces the receptors affinity for its natural hormone ligands. Mifepristone's ability to increase viral infectivity of target cells could be due to its effects on either the glucocorticoid receptor or the progesterone receptor.
To determine whether the increase in retroviral infectivity was some specific effect of mifepristone or whether it occurred with other glucocorticoid or progesterone receptor antagonists, rat PMVECs were infected with retrovirus in the presence of mifepristone or another glucocorticoid antagonist, Org 34517, kindly gifted by Schering-Plough (Kenilworth, NJ, USA). The IC 50 (half maximal inhibitory concentration) of Org 34517 for the glucocorticoid receptor is 17.9 nmol l À1 (mifepristone's IC 50 is 12.2 nmol l À1 ). 16 Org 34517 was used in a range of 0.1-30 mmol l À1 and the results were compared with rates of infectivity in nontreated or mifepristonetreated cells. Org 34517 significantly increased retroviral infectivity above control but was less potent than mifepristone. A progesterone receptor antagonist
0 oxazole]-3-one), which has an IC 50 of 0.34 nmol l
À1
for the progesterone receptor (graciously provided by RTI International, Research Triangle Park, NC, USA) (mifepristone's IC 50 for the progesterone receptor is 0.054 nmol l À1 ), had no effect on retroviral infection efficiency (Figure 6a ). 17 Adding both the specific glucocorticoid (Org 34517) and the progesterone (7453-102) receptor antagonists at the same time did not change the rate of target cell infectivity (data not shown). This suggests that the improved infection efficiency seen with mifepristone compared with Org 34517 is not due to a synergistic effect of progesterone blockade.
We next examined the effect of mifepristone on retroviral infectivity in cells that lacked either progesterone or glucocorticoid receptors. The U87MG cells (a human glioblastoma cell line) lack functional progesterone receptors, but express functional glucocorticoid receptors, 18 whereas T47D cells (a human breast cell line) express progesterone receptors, but do not have functional glucocorticoid receptors. 19, 20 Both cell lines were infected with retrovirus in the presence or absence of mifepristone. After 72 h, cells were analyzed for GFP expression (Figure 6b ). Mifepristone increased retroviral infectivity in U87MG cells, but not in T47D cells. These results, combined with those using selective progesterone and glucocorticoid receptor inhibitors, suggest that mifepristone's ability to increase retroviral infectivity of target cells is likely due to its glucocorticoid receptor antagonist properties.
Mifepristone did not enhance gamma-retroviral integration in T47D cells
As mifepristone seemed to enhance the target cell infectivity by increasing the rate of retroviral integration into the host genome, (through a glucocorticoid receptormediated action), we examined whether this effect would be lost in T47D cells. The T47D cells were infected with amphotropic MMLV for 1 h in the presence of 1 mmol l À1 of mifepristone or vehicle. Virus was then removed and cells were either analyzed immediately or incubated with mifepristone or vehicle for 6 h, or 1, 3 or 7 days. Similar to previous experiments, the total cellular DNA was isolated and resolved on a 0.8% agarose gel. The 4-kb DNA fragments (the size of nonintegrated viral DNA) and genomic DNA (450 kb) were cut out and the DNA from each fraction was extracted and analyzed for the presence of viral sequences by qPCR. Similar to 
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our results in endothelial cells (Figure 5 ), the level of free (that is, nonintegrated) viral DNA was elevated 6 h after infection and then gradually declined toward baseline (Figure 7a ). The amount of integrated viral DNA was elevated above baseline 24 h after infection in both mifepristone-and vehicle-treated cells (Figure 7b ), but unlike our results in endothelial cells ( Figure 5 ) there was no difference in the amount of either free or incorporated viral DNA at any time after infection between mifepristone-and vehicle-treated cells. Therefore, it seems that T47D cells, which lack functioning glucocorticoid receptors, are insensitive to mifepristone's ability to increase gamma-retroviral enhanced integration into the host genome. This likely explains the failure of mifepristone to increase viral infection in these cells.
Discussion
Retroviral vectors are popular and widely used gene delivery vehicles because of their efficiency and precision of integration. Retroviruses can be used to correct genetic diseases through the permanent integration of therapeutic genes into chromosomes of affected cells, for generating transgenic animals and plants, and for basic biomedical research. Determining how retroviruses infect target cells is important not only as a guide toward building better vectors, but to further our understanding of the basic biology of retroviral infection in disease.
The MMLV-derived vectors are simple and effective gene delivery vehicles in part because they tend to integrate near transcription initiation sites, dramatically increasing expression levels of delivered proteins. The biggest disadvantage of using MMLV-derived vectors is low infection efficiency. Although infected cells show a high expression level of delivered protein(s), many cells remain resistant to infection even after several infection cycles. One strategy to increase retroviral infection efficiency is to generate higher viral titers in virusproducing (packaging) cells by maximal activation of enhancers within the retroviral promoter. As MMLVderived vectors have one or more response elements within its promoter, glucocorticoids stimulate viral propagation in virus-producing cells, which leads to an increase in retroviral infectivity due to an increase in viral titer. We have shown that the glucocorticoid receptor antagonist, mifepristone, blocks this increase in viral titer. 1 However, our previous work demonstrated that although mifepristone blocked the dexamethasoneinduced increase in viral titer, it actually increased target cell infectivity. The mechanism underlying that unexpected finding was unclear. In this study, we demonstrate that mifepristone increased the number of infected target cells by facilitating the integration of the viral genome into the host genome. It did not seem to affect any other steps involved with viral infection, such as recognition of target cells, virus entry, virus stability or viral DNA synthesis.
Integration of a retroviral genome into a host chromosome completes the viral replication cycle and makes the infection permanent. The integrated viral DNA can be transcribed, resulting in RNA for translation of viral proteins and formation of viral particles, which can be released to infect other cells. Without viral integration, however, cells eventually degrade the virus and remain uninfected. Mifepristone's ability to increase retroviral infection efficiency seems to be due to its ability to facilitate retroviral integration into the host genome and thus complete the infection. Mifepristone enhanced the efficiency of viral infection in three different gammaretroviral backbones, demonstrating that its effect is not Figure 7 Mifepristone does not increase viral integration into host DNA of T47D cells. T47D cells were infected with amphotropic moloney murine leukemia virus (MMLV) for 1 h in the presence of 1 mmol l À1 mifepristone or vehicle control (using a similar protocol as described in Figure 5 ). The virus was removed by washing and cells were then cultured in fresh medium supplemented with 1 mmol l À1 mifepristone or vehicle until analysis. Nonintegrated viral and genomic DNA were separated in and extracted from a 0.8% agarose gel at same way as was described for pulmonary microvascular endothelial cells (PMVECs) and analyzed for the presence of viral DNA separately. For each time point, equal amounts of DNA were examined. (a) Quantitative PCR (qPCR) from the 4-kb fragment representing the relative amounts of nonintegrated viral DNA in mifepristone-or vehicle-treated T47D cells. (b) qPCR from the 450-kb genomic DNA representing the relative amounts of integrated viral DNA in mifepristone-or vehicle-treated cells. qPCR results in each experimental design were normalized to the signal obtained from vehicle-treated cells 1 h after infection. DNA was extracted and analyzed 1, 6 and 24 h and also 3 and 7 days after initial infection. These qPCR results were confirmed using another set of primers encoding for the internal ribosome entry site of viral DNA (present in the pBMN-GFP vector; n ¼ 4 experiments, P ¼ not significant.
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limited to a specific vector. However, mifepristone had no effect on the target cell infectivity of the two lentiviral vectors we studied. The reason for this is not clear, but may be due to the lack of functional glucocorticoid receptors or other differences in how these lentiviruses infect cells.
The exact mechanism through which mifepristone enhances viral integration in gamma-retroviruses is not clear, but it seems to involve its antagonistic effect on the glucocorticoid receptor. Another anti-glucocorticoid, Org 34517, also increased gamma-retroviral infectivity, whereas an anti-progesterone agent had no effect. Consistent with this observation, mifepristone did not increase gamma-retroviral infection efficiency in cells that lack functional glucocorticoid receptors (T47D cells), but did in those lacking functional progesterone receptors (U87MG cells).
These results suggest that inhibition of the glucocorticoid receptor enhances gamma-retroviral integration into the host genome and indicates that cells have a natural protection again viral infection that may be reduced by glucocorticoid receptor antagonists. As a research tool, mifepristone can be used to enhance gene delivery and provide a way to study different aspects involved in retroviral integration.
Materials and methods
Materials
Dexamethasone (D4902), mifepristone (M8046), hexadimethrine bromide (H9268), propidium iodide, RNase and 5 0 -bromo-2 0 -deoxyuridine were all purchased from Sigma (St Louis, MO, USA). Dulbecco's modified Eagle medium, trypsin-ethylenediaminetetraacetic acid (EDTA) and L-glutamine were all purchased from Gibco (Grand Island, NY, USA). Fetal bovine serum was purchased from Atlanta Biologicals (Lawrenceville, GA, USA). HyBond-P membrane was purchased from Amersham (Buckinghamshire, England). FuGENE 6 Transfection Reagent (11 814 443 001) was purchased from Roche Diagnostics (Indianapolis, IN, USA). Org 34517 was kindly gifted by Schering-Plough. Progesterone receptor antagonist 11b- [4-(acetyl) 
0 -methylenespiro[estra-4,9-dien-17b,4 0 -oxazole]-3-one (RTI 7453-102) was synthesized by Dr Chunyang Jin at RTI International following the previously published procedure. 17 
Cell cultures
Phoenix Retroviral Expression System ecotropic and amphotropic packaging cells were purchased from Orbigen (San Diego, CA, USA). The Pantropic Retroviral Expression System (VSV-G based, with pantropic packaging cells) was purchased from Clontech (Palo Alto, CA, USA). Rat pulmonary microvascular endothelial cells, were obtained from our cell culture core. Human glioblastoma cells (U87MG) and human mammary carcinoma cells (T47D) were obtained from ATCC (Manassas, VA, USA). All cells were cultured in Dulbecco's modified Eagle medium, 10% Fetal bovine serum, 2 mmol L-glutamine and used for experiments at passages 4-9. All cells were grown in humidified incubators at 37 1C in 5% CO 2 . Cells were collected by 0.05% trypsin/0.53 mM EDTA digestion, washed, re-suspended in cultured medium and analyzed directly by FACScan in the University of South Alabama Flow Cytometry Core. For cell cycle analysis, cellular DNA was stained with 10 mmol l À1 of propidium iodide for 20 min, as described elsewhere 21 and then analyzed by FACScan.
Vectors and delivery systems pBMN-GFP (Orbigen), a retroviral vector that expresses GFP driven by the MMLV's promoter in Phoenix and other cells was used. In some experiments, murine stem cell virus expressing mCherry and the hybrid retroviral vector friend murine embryonic stem cell virus (FMEV) (for friend mink cell focus-forming/murine embryonic stem cell virus, 4 expressing DsRed2, were used in addition to MMLV. Two lentiviral vectors pLemiR (Open Biosystems, Huntsville, AL, USA) and pLVX-DsRedMonomer-C1 (Clontech Laboratories, Mountain View, CA, USA) harboring turboRFP and DsRed as reporters were also used for comparison to gammaretroviruses. Packaging cells were transfected with retroviral vectors using FuGENE 6 reagent following the manufacturer's instructions. For virus propagation, packaging cells were cultured in growth medium for 12-18 h. Virus was collected with cultured medium, filtered, supplemented with hexadimethrine bromide (polybrene) to a final concentration of 4 mg ml À1 and applied directly to target cells.
Viral DNA measurement
The total DNA from infected cells was extracted by DNeasy Blood & tissue kit (Qiagen, Germantown, MD, USA). The level of viral DNA in total DNA extract isolated from infected cells was determined by quantitative PCR using iScript One-Step RT-PCR kit (with SYBR Green, Bio-Rad, Hercules, CA, USA; 170-8893) with primers for the GFP or the internal ribosome entry site regions of the viral DNA following the manufacturer's instructions. No reverse transcriptase was used in order to exclude contamination from a viral RNA signal. In integration studies, the total DNA isolated from infected cells was first resolved in a 0.8% agarose gel. The 4-kb DNA (the size of nonintegrated viral DNA) and genomic DNA pools (450 kb) were excised. The DNA from each fraction was extracted and analyzed for the presence of viral sequences by qPCR as previously described.
Statistical analysis
Data are expressed as mean ± s.e. values, changes in cell cycle profile, infectivity and changes in fluorescent protein expression were compared using analysis of variance combined with Fisher post-hoc analysis, with a P-value o0.05 considered as significant.
